Front. PsychiatryFrontiers in PsychiatryFront. Psychiatry1664-0640Frontiers Media S.A.10.3389/fpsyt.2016.00035PsychiatryOriginal ResearchDNA Methylation at the Neonatal State and at the Time of Diagnosis: Preliminary Support for an Association with the Estrogen Receptor 1, Gamma-Aminobutyric Acid B Receptor 1, and Myelin Oligodendrocyte Glycoprotein in Female Adolescent Patients with OCDNissenJudith Becker1*HansenChristine Søholm2StarnawskaAnna345MattheisenManuel345BørglumAnders Dupont345ButtenschønHenriette Nørmølle6HollegaardMads2†1Center of Child and Adolescent Psychiatry (BUC), Aarhus University Hospital, Risskov, Denmark2Department of Congenital Diseases, Neonatal Genetics, Statens Serum Institut, Copenhagen, Denmark3Department of Biomedicine, Aarhus University, Aarhus, Denmark4The Lundbeck Foundation Initiative for Integrative Psychiatric Research (iPSYCH), Aarhus, Denmark5Centre for Integrative Sequencing (iSEQ), Aarhus, Denmark6Translational Neuropsychiatry Unit (TNU), Department of Clinical Medicine, Aarhus University, Aarhus, Denmark
Edited by: Chad A. Bousman, University of Melbourne, Australia
Reviewed by: Jeffrey Mark Craig, Murdoch Childrens Research Institute, Australia; Joanne Ryan, Murdoch Childrens Research Institute, Australia
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
Obsessive–compulsive disorder (OCD) is a neuropsychiatric disorder. Non-genetic factors and their interaction with genes have attracted increasing attention. Epigenetics is regarded an important interface between environmental signals and activation/repression of genomic responses. Epigenetic mechanisms have not previously been examined in OCD in children and adolescents. The aim of the present study was to examine the DNA methylation profile of selected genes in blood spots from neonates later diagnosed with OCD and in the same children/adolescents at the time of diagnosis compared with age- and sex-matched controls. Furthermore, we wanted to characterize the association of the differential methylation profiles with the severity of OCD and treatment outcome. Dried and new blood spot samples were obtained from 21 female children/adolescents with verified OCD and 12 female controls. The differential methylation was analyzed using a linear model and the correlation with the severity of OCD and treatment outcome was analyzed using the Pearson correlation. We evaluated selected Illumina Infinium HumanMethylation450 BeadChip probes within and up to 100,000 bp up- and downstream of 14 genes previously associated with OCD (SLC1A1, SLC25A12, GABBR1, GAD1, DLGAP1, MOG, BDNF, OLIG2, NTRK2 and 3, ESR1, SL6A4, TPH2, and COMT). The study found no significantly differential methylation. However, preliminary support for a difference was found for the gamma-aminobutyric acid (GABA) B receptor 1 (cg10234998, cg17099072) in blood samples at birth and for the estrogen receptor 1 (ESR1) (cg10939667), the myelin oligodendrocyte glycoprotein (MOG) (cg16650906), and the brain-derived neurotrophic factor (BDNF) (cg14080521) in blood samples at the time of diagnosis. Preliminary support for an association was observed between the methylation profiles of GABBR1 and MOG and baseline severity, treatment effect, and responder status; and between the methylation profile of ESR1 and baseline severity. To our knowledge, this is the first study to examine the DNA methylation profiles in OCD. The study points towards possible differences in the methylation profiles and suggests a correlation with the severity of OCD. However, the results warrant further studies in larger sample sets.
Obsessive–compulsive disorder (OCD) is a frequently encountered neuropsychiatric disorder with prevalence rates among children and adolescents comparable to those of the adult population (1–3%) (1). It is characterized by obsessions, i.e., intrusive thoughts that are unpleasant and frightening, and which the affected individuals attempt to resist or reject and by compulsions, i.e., repetitive, often stereotypic movements or mental rituals, which are semi-voluntary and performed to reduce the fear/anxiety or bodily reaction. OCD is a heterogeneous disorder in regard to its clinical presentation and treatment response (2–4). Its complex nature has likely complicated efforts to identify causal mechanisms associated with this disorder.
Both genetic and non-shared environmental factors are important in the etiology of OCD. Based on separate twin modeling analyses, a recent population-based study suggested that the increased familial risk of OCD was attributable to additive genetic factors (47%). No significant effect could be shown for shared environmental factors, whereas non-shared environmental factors were estimated to be as important as the genetic factors (5).
According to several review articles, genes affecting different neurotransmitter systems, neurotrophic factors, and sex hormones have been implicated in OCD (6, 7). It has been suggested that these systems form a delicate network of interacting components (8). However, as described in the review articles, results have been divergent. In association studies, the most stable association has been related to SLC1A1, the neuronal glutamate transporter gene, which encodes the glutamate transporter EACC1 (9) (Table 1). Other components of the glutamatergic system have also been associated with OCD. These components include genes encoding for the GABA B receptor (GABBR1) (10), glutamate decarboxylase 1 (GAD 1) (11), and Disks large-associated protein 1 (DAP-1) (DLGAP1) (12) (Table 1). Both the GABA B receptor and Gad67 are important in regulating the activity of glutamate, and DAP-1 is a member of the neuronal postsynaptic density complex known to be important in relation to the glutamatergic system. Furthermore, myelin oligodendrocyte glycoprotein (MOG) has been associated with OCD and with the severity of OCD. Moreover, the MOG G511C (Val142Leu) Val/Val genotype has been associated with morphological changes in the total white matter volume in patients with OCD (13). Zai and coauthors (14) showed an association of genetic variants and haplotypes within the MOG gene with a further association to the severity of OCD (Table 1). The serotonin transporter is a main target for the selective serotonin reuptake inhibitors (SSRIs), and several studies have investigated the association between variants within the gene encoding the serotonin transporter (SLC6A4) and OCD. Positive associations with especially early onset OCD have been identified (6, 15) (Table 1). Also, the brain-specific tryptophan hydroxylase-2 (TPH-2) enzyme involved in the synthesis of serotonin has been associated with OCD (16). On the contrary, studies of variations in the COMT gene have shown conflicting results (6). However, a recent study by Alonso et al. showed an association between dysfunctional beliefs assessed by the Obsessive Beliefs Questionnaire (OBQ-44) and an interaction between the Val158Met variant in the COMT gene and the Val66Met variant in the BDNF gene rather than an effect of either variant (17). Other studies have also suggested an association between neurotrophic factors and OCD. Hall et al. showed a strong association between BDNF gene variants and OCD (18) pointing towards possible risk alleles (including the Val66Met BDNF polymorphism). These findings have later been replicated by Hemmings et al. (19) and Katerberg et al. (20). Furthermore, Márquez et al. have shown a significant association between the occurrence of OCD and genetic variation at certain BDNF loci suggesting a role for BDNF in the development of OCD (21). Furthermore, the BDNF Val66Met polymorphism has been implicated in the increased risk of OCD resulting from trauma experienced during childhood (22). Additionally, it has been suggested that sex hormones may be implicated in the development or the worsening of OCD. Forray et al. (23) showed a relation between pregnancy and the onset of OCD. Furthermore, compared to other women, women with onset or worsening of OCD perinatally experienced a worsening of their OCD in relation to their menstrual period. Alonso et al. (24) investigated the association between variants in the estrogen receptor genes (ESR1 and ESR2) and the occurrence of OCD. Although no direct association was observed, they found that certain OCD subphenotypes (contamination obsessions and cleaning compulsions) were associated with both a SNP in the ESR1 gene (rs34535804) and a five-marker haplotype in the ESR1 (5′ end of intron 1). These findings suggest that the ESR1 gene could contribute to the genetic vulnerability associated with OCD manifestations. Furthermore, a study examining the severity of Post Traumatic Stress Disorder (PTSD) (often including anxiety and OCD) showed that a low level of estradiol could promote stronger PTSD symptoms and could be associated with poorer fear extinction (25) (Table 1). Apart from the association to Disks large-associated protein 1 (DAP-1) (DLGAP1), two recent genome-wide association studies (GWAS) were not able to replicate the findings from the candidate gene studies described above (12, 26). Since several of the associations were described either as a combined effect or as being related to epidemiological factors, a possible explanation is that the systems exert their effect through a delicate network of mutual influences that also involve environmental factors influencing the gene transcription and expression. Epigenetics is regarded an important interface between environmental signals and activation or repression of genomic responses. The mechanisms are dynamic and interchangeable over time. Through different mechanisms including modifications of DNA molecules, the epigenetic mechanisms regulate the accessibility for transcription factors and influence gene expression (27). The role of epigenetics in anxiety disorders has been underlined in studies examining the mechanisms of fear-related learning and memory involving histone acetylation [reviewed in Ref. (28), where different anxiety mechanisms and stress are discussed]. Furthermore, anxiety also involves DNA methylation mechanisms where DNA methyltransferases are activated by fear learning and associated with methylation within the promoter region of the gene encoding the protein phosphatase (28). In a publication from 2013, Domschke et al. showed a significantly lower GAD1 methylation in adults with panic disorder than in age- and sex-matched healthy controls, and the occurrence of negative life events correlated with the decreased average methylation in a sex-differentiated manner. The authors suggested that the hypomethylation could be a compensatory reaction (29). A recent study examined the methylation of SLC6A4 in children with anxiety disorder (30). The children were treated with cognitive behavioral therapy (CBT). An evaluation of the total group showed no differences in the methylation profiles, but comparison of responders with non-responders showed an increased methylation in one CpG-site of the SLC6A4 promotor region in the responders (29). Even though several studies have examined epigenetic mechanisms in psychiatric disorders including in anxiety disorders, which are closely related to OCD, no study has examined epigenetic mechanisms in relation to OCD.
In the present study, we wanted to examine the methylation profile in selected genomic regions in children and adolescents diagnosed with OCD compared with age- and sex-matched controls. Furthermore, we wanted to compare the methylation profiles at birth and after OCD onset. Finally, we investigated the association of the methylation profiles with the severity of OCD and with treatment effect. To the best of our knowledge, this is the first study to examine the implication of epigenetics mechanisms in OCD in a population of children and adolescents.
Materials and Methods
Permission to perform the study was granted by the Scientific Ethics Committee (1-10-72-149-12).
Children and adolescents were recruited through referrals from general practitioners, child mental health specialists, or pediatricians. All the children and adolescents were examined and diagnosed in the specialized OCD clinic in Aarhus, Denmark, by a team consisting of experienced and skilled psychologists and a child and adolescent psychiatrist. For diagnostic assessment, we used questions concerning obsessive–compulsive symptoms and comorbidity from The Schedule for Affective Disorders and Schizophrenia for School-Age Children Present and Lifetime Version (K-SADS-PL) (31). The Children’s Yale–Brown Obsessive–Compulsive Scale (CY-BOCS) (32) was used for assessment of severity scores at baseline and after treatment with CBT. The CY-BOCS is a clinician-administered instrument that evaluates obsessions and compulsions separately on time consumed, distress, interference, resistance, and control. It yields separate severity scores for obsessions and compulsions (0–20) and a composite severity score (0–40). The CY-BOCS scores were obtained at the time of diagnosis (defined as pre-treatment CY-BOCS scores) and at 13 weeks or at dismissal (defined as post-treatment CY-BOCS scores).
Age- and sex-matched controls were recruited through advertising at schools and a subsequent contact to parents through email or telephone. If the child or adolescent wanted to participate, a short interview was conducted that included questions on anxiety and OCD (ever experienced symptoms). Only information on females is presented, since the total number of males was very low.
The neonatal blood spot samples from Guthrie cards (referred to as “OLD samples” in the following sections) were obtained from the Danish Neonatal Screening Biobank (DNSB) located in the Statens Serum Institut (SSI). New blood spots (referred to as “NEW samples” in the following sections) were collected from a fingertip on S&S903 filter paper (33) (GA Whatman) from the same individuals at the time of diagnosis. As such, OLD samples (neonatal blood samples) and NEW samples were from the same individuals, but the samples were taken at different time points. Before collecting the blood from the fingertips, the finger was cleaned with a wipe with isopropyl alcohol. Next, the area was air-dried, and the insert was carried out with a lancette (Microlet, Bayer, Germany). The first drop of blood was dried up. A large drop of blood was allowed to form on the finger, and then the center of the pre-printed circles on filter paper was gently placed on the droplet so that it was absorbed. Blood spots were dried at room temperature for about 3 h and then kept frozen (−20°C) until analysis.
DNA was extracted from the filter paper as previously described (34, 35). The epigenetic analysis was conducted using the Illumina Infinium HumanMethylation450 Beadchip (Illumina San Diego, CA, USA). The degree of methylation was examined by beta-values. This method describes the percentage methylation of a CpG probe [beta = methylated/(methylated + unmethylated)].
We investigated genes in the glutamatergic (SLC1A1, SLC25A12, GABBR1, GAD1, DLGAP1, MOG), the serotonergic (SLC6A4, TPH2), and the dopaminergic systems (COMT), as well as neurotrophic genes (OLIG2, NTRK3, NTRK2, BDNF), and the sex hormone receptor (ESR1) (Table 2). The genes and their CpGs tags (all CpGs 100,000 bp up and downstream from the open reading frame – 1,486 CpG probes) were selected based on hypotheses about gene location, gene function, and the results from association studies in relation to OCD (Table 1). The selection of CpG sites was performed due to the small sample size.
Overview of the genes tested for a hypothesized association with OCD and the number of probes included 100,000 bp up and down stream of the genetic region – *413 probes were overlapping between GABBR1 and MOG (GABBR1/MOG).
Systems
Gene
Probes (count)
Methylated variable positions (limma) Case vs. ctrl
OLD (case: N = 21, control: N = 11)
NEW (case: N = 21, control: N = 12)
Glutamatergic system
SLC1A1
28
NS
NS
SLC25A12
47
NS
NS
GABBR1
519*
NS
NS
^cg10234998* (GABBR1, TSS1500),p-val: 0.00023/FDR p 0.18,Fold-change (case/ctrl): 1.14
^cg17099072* (GABBR1, TSS1500)p-val: 0.00026/FDR p 0.18Fold-change (case/ctrl): 1.12
GAD1
87
NS
NS
DLGAP1
103
NS
NS
MOG
571*
NS
NS
^cg10234998* (GABBR1, TSS1500),p-val: 0.00023/FDR p 0.18,Fold-change (case/ctrl): 1.14
^cg16650906 (LOC285830, body)p-val: 0.00017/FDR p 0.12,Fold-change (case/ctrl): 0.976
^cg17099072* (GABBR1, TSS1500)p-val: 0.00026/FDR p 0.18
Fold-change (case/ctrl): 1.12
Neurotrophic factors
BDNF
86
NS
NS
^cg14080521 (BDNF-AS, IGR)p-val: 0.00031/FDR p 0.14,Fold-change (case/ctrl): 0.98
OLIG2
82
NS
NS
NTRK3
51
NS
NS
NTRK2
19
NS
NS
Sex hormone
ESR1
73
NS
NS
^cg10939667 (ESR1, Body) p-val: 0.00016/FDR p 0.12,Fold-change (case/ctrl): 0.98
Serotonergic system
SLC6A4 (SERT)
63
NS
NS
TPH2
42
NS
NS
Dopaminergic system
COMT
128
NS
NS
NS, not-significant describes that a FDR corrected p-value of <0.05 was not achieved for any genetic region. However, we have mentioned (bold writing) the top three probes that had p-values <0.2 for each methylation variable position analysis (OLD and NEW) (see the full list of p-values as in Supplementary Material). ^The top three probes with p-values <0.2 are written in bold writing, and location abbreviation of the probe position relative to the gene are: TSS1500, 1500 bp upstream from transcription start site; body, in gene body; IGR, intergenic region.
DNA Methylation Variable Positions
The methylation profiles were examined by comparing methylation beta-values of OCD patients from blood obtained at the time of diagnosis (NEW case) with healthy controls (NEW control) of comparable age distribution and birth year. Likewise, methylation profiles were compared in neonatal blood from the same patients (OLD case) and controls (OLD control) obtained from the DNSB. For statistical methylation variable positions (MVP) analysis, we used the ChAMP package in R (36). Raw data was filtered to remove probes with detection p-value >0.01 and bead count <3. Likewise, probes aligning to multiple locations and containing SNPs identified by Nordlund et al. (37) were also removed. No X and Y chromosome hybridizing probes were included in this study. This resulted in a total of 434,493 passed probes of the 485,512 probes in the Illumina Human Methylation 450k array. The data were normalized by the SWAN method and converted to beta values hereafter batch corrected for technical variation by the combat method build into the ChAMP package pipeline.
After filtering with the list of 1,486 hypothesized OCD probes (CpG probes located ± 100.000 bp from the genetic reading frame of the selected genes, SLC1A1, GABBR1, GAD1, DLGAP1, MOG, TPH2, OLIG2, NTRK3, NTRK2, ESR1, SLC25A12, SLC6A4, COMT, and BDNF), 1,368 probes were included for further analysis, and the remaining were not used further in this study.
Beta values were chosen due to the small sample size. The probes were filtered for Det P < 0.01, and a sample Call Rate >99% was used (all samples met these criteria). MVPs between the case and control group for either the NEW or OLD samples were investigated using a linear model across all selected probes, and correction for multiple testing was applied by the false discovery rate method (FDR).
Top ranking genes from the MVP association were associated with the severity scores (CY-BOCS). Probes ± 100,000 bp up/downstream of ESR1, MOG, and BDNF were analyzed for the NEW cases only; and probes ± 100,000 bp up/downstream of GABBR1 and MOG were analyzed for the OLD cases only.
The association between the methylation status and the severity of OCD was examined by correlating the methylation status and the baseline CY-BOCS score at the time of diagnosis and the CY-BOCS differences (post-treatment CY-BOCS scores subtracted from baseline CY-BOCS scores). The analysis was performed in R by applying the Pearson correlation test between scores and probe methylation status across all evaluated probes. We corrected for multiple testing using the FDR method.
Treatment response was assigned to cases having a CY-BOCS <16 at the end of treatment (week 13). Responder methylation status was compared with non-responder methylation status by a double-sided t-test across all probes. We corrected for multiple testing using the FDR method.
Differential Analysis
The difference between methylation status at birth and at the time of diagnosis between cases and controls was assessed by differential methylation analysis on delta-beta-values [beta-values (OLD) minus beta-values (NEW)] with a linear model analysis in the ChAMP pipeline between cases and controls. We corrected for multiple testing using the FDR method.
ResultsDemographic Description of the Cohorts
The clinical population consisted of 21 female children and adolescents (13.29 ± 2.63) with verified OCD according to the ICD-10. The clinical cohort was age- and sex-matched with controls; it included 12 females (13.17 ± 2.48) in the NEW cohort and 11 females (13.18 ± 2.60) in the OLD cohort. The severity of the OCD in cases at baseline/pre-treatment was 25.86 ± 5.00 and at post-treatment 14.71 ± 5.66 (Table 3). The occurrence of comorbid psychiatric disorders is shown in Table 4. Out of the 21 patients, 8 patients had one comorbid disorder, and 5 patients had more than one comorbid disorder (2 or 3 comorbid disorders). None of the matched controls had ever experienced OCD or anxiety symptoms.
Sample statistics of age and OC symptom severity.
Sample statistics
Case female N = 21 (NEW and OLD)
Control female
N = 12 (NEW)
N = 11 (OLD)
Age
13.29 ± 2.63
13.17 ± 2.48
13.18 ± 2.60
Birth year
1999 ± 2.5
2000 ± 2.6
2000 ± 2.7
CY-BOCS baseline
25.86 ± 5.00
NA
CY-BOCS at 13 weeks/dismissal
14.71 ± 5.66
NA
Comorbidity
13/21 (61.9%)
NA
In the case group, 21 females with clinically diagnosed OCD have been analyzed for their methylation profile at birth (OLD) and at the clinical time of diagnosis (NEW). The 12 females of comparable age distribution were included as NEW controls, and 11 of these were included as neonatal controls (OLD) – of comparable birth year distribution. Age, year/months, and OC symptom severity (±SD).
The occurrence of comorbid disorders in the case group (N = 21) described in accordance with the ICD 10 diagnostic sub-classification.
Comorbidity
Case female
N = 21 (NEW and OLD)
Mood disorders
2
Anxiety disorders
4
Trichotillomania
1
Developmental disorders
3
Hyperkinetic disorder
1
Conduct disorder
1
Emotional disorders
6
Tic disorders
4
MVP Analysis
The microarray analyses included 21 OLD and NEW case pairs, 11 OLD controls, and 12 NEW controls.
Comparison of the methylation profiles of female OCD subjects (NEW) with the methylation profiles of control subjects (NEW) revealed no significant differences in the methylation of CpG sites associated with the selected genes. The top-three most altered methylation sites in terms of p-value were seen in the body of the LOC285830 gene within the chosen range (100,000 bp) of the MOG gene on chromosome 6 (probe cg16650906), in the vicinity of the BDNF gene on chromosome 11 (probe cg14080521), and in the gene body of the ESR1 gene on chromosome 6 (probe cg10939667). For all sites, the fold-change (case/control) was 0.98 showing a 2% difference between the cases and the controls. In blood samples at birth (OLD), the most altered methylation sites were in the GABBR1 gene overlapping with the MOG gene selected probes on chromosome 6 (probes cg10234998 and cg17099072). The two probes were located close to each other (only 2 bp apart) near the GABBR1 transcription start site (TSS1500 shore – within 1500 bp of the transcription start site) (Table 2). The fold-change (case/control) was 1.14 and 1.12, respectively.
No significant MVPs were found in the longitudinal analysis of the delta-beta values (OLD-NEW). Still, like in the OLD sample MVP analysis, the two same GABBR1/MOG probes (cg17099072 and cg10234998), as found in the OLD sample MVP analysis, showed a differential methylation (FDR p-value 0.135 for both) with a fold change (case/control) in delta-beta values of 1.88 and 1.45, respectively. This effect appears to be inherent from the MVP seen in the OLD cohort MVP analysis, where the more methylated OLD cases no longer show support for a differentially methylation in the NEW cases compared with their respective controls (FDR p-values 0.664 and 0.956, respectively).
Severity Score (CY-BOCS) and Treatment Responder Status Associated With Methylation Status in Selected Probes
In relation to the severity scores (CY-BOCS), we analyzed the probes associated with the MVP top hits both for NEW cases: ESR1, MOG (inherently some GABBR1/MOG overlapping probes) and BDNF, and for OLD cases: GABBR1 and MOG. Neither significant association was found between the methylation profiles in the OLD cases and baseline CY-BOCS nor were any differences found between baseline and differences in CY-BOCS scores (post-treatment compared with baseline CY-BOCS scores). However, a MOG-associated probe in a CpG island near the gene IFITM4P (cg15395148, r = −0.7) had a lower p-value than the remaining samples (association to baseline CY-BOCS score), and a probe in a CpG island at the 5′ UTR end of the GABBR1 gene showed the same tendency (cg19456996, r = −0.7) (association to the differences in CY-BOCS scores).
We investigated the correlation of the baseline CY-BOCS and CY-BOCS difference in the NEW cases with the methylation status of the selected NEW probes and found none of the probes to be significantly associated with the scores. However, one ESR1 probe in the 5′ UTR end of the gene (cg25565730, r = −0.68) and two probes selected for MOG, but located within the GABBR1 gene (cg08967211 and cg17071948, r = −0.64 and −0.65), showed a lower p-value than the remaining probes.
Finally, in NEW samples, there was a preliminary support for a positive association between the responders and the methylation state of probes near the MOG gene, where the top scoring probe was located in the GABBR1 gene body [cg16922688, fold change (responder/non-responder) = 1.02], while two probes in the TSS1500 of the LOC285830 gene, only 9 bp apart (cg09567915 and cg11497864) exhibited the same tendency of association with comparable fold changes of 1.26 and 1.27, respectively (Table 5).
Top hit genes from MVP analysis of NEW (N = 21) (ESR1, MOG, and BDNF) and OLD (MOG and GABBR1) association with CY-BOCS baseline (A), CY-BOCS difference from admission until the end of treatment (B) and patient responsiveness to treatment (C) evaluated as a CY-BOCS <16 at the end of treatment.
(A) CY-BOCS BASELINE
CpG
Gene
RefGENE/feature
Corr r-value
p-value
FDR p-value
NEW case (N = 21)
cg25565730
ESR1
ESR1, 5′ UTR
−0.68
0.0007
0.39
cg08967211
GABBR1/MOG
GABBR1, body
−0.64
0.0016
0.39
cg17071948
GABBR1/MOG
GABBR1, body
−0.64
0.0018
0.39
OLD case (N = 21)
cg15395148
MOG
IFITM4P, IGR
−0.70
0.00043
0.26
cg06613392
GABBR1
UBD, IGR
−0.65
0.00157
0.48
cg19348622
GABBR1/MOG
HLA-F, body
−0.60
0.00438
0.89
(B) CY-BOCS DIFFERENCE
CpG
Gene
RefGENE/feature
Corr r-value
p-value
FDR p-value
NEW case (N = 21)
cg06380702
MOG
IFITM4P, IGR
−0.64
0.0019
0.68
cg24764793
ESR1
ESR1, 5′ UTR
−0.59
0.0050
0.68
cg10601943
GABBR1/MOG
HLA-F, body
−0.59
0.0051
0.68
OLD case (N = 21)
cg1945699
GABBR1/MOG
GABBR1, 5′ UTR
−0.70
0.00039
0.24
cg01306985
MOG
IFITM4P, TSS1500
−0.62
0.0027
0.52
cg12296326
MOG
LOC285830, TSS1500
−0.60
0.0037
0.52
(C) TREATMENT RESPONDER
CpG
Gene
RefGENE/feature
Fold-change
p-value
FDR p-value
NEW case (N = 21)
cg16922688
GABBR1/MOG
GABBR1, body
1.02
0.00042
0.15
cg09567915
MOG
LOC285830, TSS1500
1.26
0.00048
0.15
cg11497864
MOG
LOC285830, TSS1500
1.27
0.00068
0.15
OLD case (N = 21)
cg08541345
MOG
LOC285830, body
1.30
0.0014
0,52
cg16118803
GABBR1/MOG
MOG, body
1.17
0.0019
0.52
cg12463578
GABBR1/MOG
ZFP57, first exon
0.84
0.0028
0.52
A and B reflect the correlation between severity scores and beta-values, while C reflects the most different hits between responders and non-responders tested by a parametric t-test, and fold change describing the responder/non-responder ratio in the mean beta-value. All p-values are corrected for multiple testing by the FDR method. RefGENE/Chr denotes the exact genetic location of the three top-hit probes in each category. 5′ UTR, 5′ untranslated region; body, gene body; IGR, intergenic region; TSS1500, within 1500 bp of transcription start site; first exon, in the first exon. Gene investigated by probes in its genetic region and 100,000 bp up/downstream. Exact RefGene and feature of the probe is annotated for all top-hit genes in this table.
Discussion
The present study examines the methylation profiles of genes hypothesized to be important in OCD in children and adolescents. To the best of our knowledge, no other study has investigated the methylation status in OCD in children and adolescents or examined the difference between methylation status at birth and at the time of the OCD diagnosis.
In the present study, differential methylation analysis between case and control was performed based on a hypothesis-driven selection of genes. We found no MVPs. However, CpG probes in GABBR1 and MOG (OLD samples) and probes in MOG, BDNF and ESR1 (NEW samples) had the lowest p-values. In OLD samples, the study supported an increased methylation of probes associated with GABBR1/MOG, whereas in NEW samples, cases showed a slightly lower degree of methylation of a CpG in ESR1. The extent of modification required in order to achieve functional significance is largely unknown. However, methylation changes in blood are influenced by the heterogeneous nature of the tissue, and markers associated with diseases in the brain are known to be of a smaller effect size when analyzed in blood (38).
Previous studies have shown a reduced expression of BDNF in relation to anxiety disorders and OCD (39), which could be caused by a possible differential methylation in the BDNF gene. BDNF has been implicated in fear extinction where it has been suggested that the serotonergic and glutamatergic systems may mediate their effects on fear through the BDNF gene expression (40, 41). Thus, an altered methylation of BNDF probes could reflect an altered risk of expressing OCD.
To our knowledge, no previous study has examined the methylation status of ESR1 in relation to OCD or anxiety. It has been suggested that estrogen receptor genes play a role in relation to OCD (24). Even though Alonso et al. could not show any difference between controls and subjects with the categorical OCD phenotype, their study identified genetic variants that were associated with the presence of certain OCD symptoms. This finding suggests that the ESR1 gene could contribute to the genetic vulnerability to OCD manifestations. In the present study, we observed a tendency towards a reduced methylation in NEW female cases compared with NEW female controls and tendency towards an inverse correlation between the methylation of ESR1 and the pre-treatment severity of OCD (as evaluated by the CY-BOCS score). Interestingly, that the altered methylation of the ESR1 gene was observed only in NEW samples from female cases; that is in females in their teens where estrogens become increasingly important and where the sex ratio observed in relation to OCD is altered. We only conducted the analyses for females, but other studies have shown a sex difference in relation to the expression of ESR. For example, Delgrange et al. (49) showed that the expression of ESR1 was inversely correlated with the size and proliferative activity of a prolactin pituitary tumor. This finding could suggest a sex-specific receptor expression. The associated probes are located in the gene body and in the 5′ end of the gene on chromosome 6, respectively. These locations do not rule out a regulatory role, and the results could suggest that the percentage methylation of the CpG probe plays an important role for OCD in females, and for the severity of the disorder. This finding would be in accordance with the association between the expression of ESR1 and the prognosis of pituitary tumor (47) and with the proposed exacerbating role of a low level of estradiol on PTSD and the described poorer fear extinction (25). To explore the importance of the expression of ESR1 in relation to OCD further, future studies could evaluate the degree of methylation correlated with the pubertal development in females.
The MOG gene encodes the MOG which is thought to be important in the myelination of nerves potentially providing the structure of myelin sheath and also in relation to the immune system (13, 14). The GABBR1 gene encodes the gamma-aminobutyric acid (GABA) B receptor 1 (GABAB1) (10). Through the GABAB1 receptor, GABA is thought to fine-tune the inhibitory synaptic transmission including the effect of glutamate, which has been associated with the occurrence of OCD. In the present study, probes for the two genes were overlapping showing a potential regulatory role for one or both genes. Both GABBR1 and MOG showed altered methylation in the blood samples at birth (OLD). This may suggest that they are important to the developing brain where we may hypothesize that early alterations alter the risk of later developing OCD. Both GABA receptor signaling and glutamate have been implicated in proliferation, migration, differentiation, and survival processes with a differential expression over lifetime (50). The altered methylation of GABBR1/MOC observed in the newborn children, however, seemed to stabilize to control levels from OLD to NEW cases, as shown by the differential longitudinal analysis of the most significant changes from OLD to NEW. MOG (LOC285830) showed an altered methylation in the NEW samples. The MOG gene has been associated with the presence of OCD, and it has also been related to the severity of the disorder. Furthermore, it has been related to changes in white matter and to inflammatory processes (13, 14). It is not known whether the observed changes arise before the OCD onset or if they could be a consequence of having OCD. However, the observed tendency towards altered methylation in cases compared with controls and in relation to the severity of the disorder and the responder status could suggest a regulatory role.
Since methylation levels are not confined to single probes, but are more likely to affect entire regions causing differentially methylated regions, most of these tendencies may be seen as possible candidates for future investigation. However, the closely related LOC285830 transcription start site probes placed in the vicinity of the MOG gene appeared to exhibit uniformly higher methylation level in treatment responders compared with non-responder in the adolescent OCD patients. Furthermore, the consistent tendency of the GABBR1 transcription start site probes to have at higher methylation level in newborn cases compared with controls reveals that epigenetic regional methylation levels might indeed be involved in the pathogenesis of OCD, even if no overall differentially methylated regions were identified in this study.
Limitations
The present study includes only very few patients and controls. Nevertheless, it reached nominally significant results and gave preliminary support for an association between the methylation of ESR1, GABBR1, and MOG and the severity of the OCD and treatment outcome. However, due to the limited number of patients and controls, the study did not account for potentially confounding factors, including parental smoking or illnesses in cases/controls at birth. Furthermore, the investigated genes were not selected based on GWAS results, which have shown different results than candidate gene studies. However, in view of the limited number of patients and controls, we chose to focus on hypothesis-driven selected genes in a cohort of females. We are collecting additional blood specimen from children and adolescents with OCD as to perform a future epigenome-wide association study. Specimen from the central nervous system would have been optimal for examining the methylation patterns. However, by necessity, the DNA was extracted from peripheral blood rather than from central nervous tissue. It has been discussed in previous articles that even though the epigenome does show tissue-specific patterns, epigenetic modifications may be detectable across tissues (51, 52). The specific positions of the probes we have examined in the present study and the indicated methylation differences are not assessed for their gene regulatory functions. However, a larger study providing significant MVPs and especially differentially methylated regions would be able to link the methylation changes to the annotated genetic regions and to speculate on the biological significance.
The findings do not explain the implicated mechanisms, i.e., the nominal differences in methylation may be either the cause or the result of OCD. Nevertheless, the study supports the hypothesis that epigenetic factors are of importance in mental disorders.
Ethical Considerations
The study was approved by the ethics committee and was conducted in accordance with the latest version of the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments. Informed consent was obtained from the participants after the nature of the procedures had been fully explained.
Author Contributions
All authors listed, have made substantial, direct, and intellectual contribution to the work, and approved it for publication. However, MH only approved the first edition of the manuscript, since he passed away before the final edition was ready.
Conflict of Interest Statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
The study was funded by AUFF Ideas, project number 438387/Ideas, Aarhus University, Denmark.
Supplementary Material
The Supplementary Material for this article can be found online at http://journal.frontiersin.org/article/10.3389/fpsyt.2016.00035
ReferencesGellerDABiedermanJJonesJShaoiroSSchwartzSParkKS. Obsessive-compulsive disorder in children and adolescents: a review. Harv Rev Psychiatry (1998) 5:260–73.10.3109/106732298090003099493948SobinCBlundellMLKarayiorgouM. Phenotypic differences in early- and late obsessive-compulsive disorder. Compr Psychiatry (2000) 41:373–9.10.1053/comp.2000.9009NestadtGAddingtonASamuelsJLiangK-YBienvenuOJRiddleMThe identification of OCD-related subgroups based on comorbidity. Biol Psychiatry (2003) 53:914–20.10.1016/S0006-3223(02)01677-312742679Rosario-CamposMCLeckmanJFMercadanteMTShavittRGPradoHSSadaPAdults with early-onset obsessive-compulsive disorder. Am J Psychiatry (2001) 158(11):899–903.Mataix-ColsDBomanMMonzaniBRuckCSerlachiusELangstromNPopulation-based, multigenerational family clustering study of obsessive-compulsive disorder. JAMA Psychiatry (2013) 70:709–17.10.1001/jamapsychiatry.2013.323699935WalitzaSWendlandJRGruenblattEWarnkeASontagTATuchaOGenetics of early-onset obsessive-compulsive disorder. Eur Child Adolescs Psychiatry (2010) 19:227–35.10.1007/s00787-010-0087-720213231PaulsDL. The genetics of obsessive-compulsive disorder: a review. Dialogues Clin Neurosci (2010) 12(2):149–63.20623920PaulsDLAbramovitchARauchSLGellerDA. Obsessive-compulsive disorder: an integrative genetic and neurobiological perspective. Nat Rev Neurosci (2014) 15:410–24.10.1038/nrn374624840803DickelDEVeenstra-VanderWeeleJCoxNJWuXFischerDJVan Etten-LeeMAssociation testing of the positional and functional candidate gene SLC1A1/EAAC1 in early-onset obsessive-compulsive disorder. Arch Gen Psychiatry (2006) 63(7):778–85.10.1001/archpsyc.63.7.77816818867ZaiGArnoldPBurroughsEBarrCLRichterMAKennedyJL. Evidence for the gamma-amino-butyric acid type B receptor 1 (GABBR1) gene as a susceptibility factor in obsessive–compulsive disorder. Am J Med Genet B (Neuropsych Genet) (2005) 134B:25–9.10.1002/ajmg.b.30152MasSPageroisMGassoPOrtizARodriquezNMorerARole of GAD2 and HTR1B genes in early-onset obsessive-compulsive disorder: results from transmission disequilibrium study. Genes Brain Behav (2014) 13(4):409–17.10.1111/gbb.1212824571444StewartSEYuDScharfJMNealeBMFagernessJAMathewsCAGenome-wide association study of obsessive-compulsive disorder. Mol Psychiatry (2013) 18(7):788–98. Davis LK. Erratum in Mol Psychiatry (2013) 18(7):84310.1038/mp.2012.8522889921AtmacaMOnalanEYildirimHYuceHKocMKorkmazS. The association of myelin oligodendrocyte glycoprotein gene and white matter volume in obsessive-compulsive disorder. J Affect Disord (2010) 124(3):309–13.10.1016/j.jad.2010.03.02720452030ZaiGBezchlibnykYBRichterMAArnoldPBurroughsEBarrCLMyelin oligodendrocyte glycoprotein (MOG) gene is associated with obsessive-compulsive disorder. Am J Med Genet B Neuropsychiatr Genet (2004) 129B(1):64–8.10.1002/ajmg.b.3007715274043WalitzaSWewetzerCGerlachMKlampflKGellerFBarthNTransmission disequilibrium studies in children and adolescents with obsessive–compulsive disorders pertaining to polymorphisms of genes of the serotonergic pathway. J Neural Transm (2004) 111:817–25.MössnerRWalitzaSGellerFScheragAGutknechtLJacobCTransmission disequilibrium of polymorphic variants in the tryptophan hydroxylase-2 gene in children and adolescents with obsessive-compulsive disorder. Int J Neuropsychopharmacol (2006) 9:437–42.10.1017/S146114570500599716146581AlonsoPLópez-SolàCGratacósMFullanaMASegalàsCRealEThe interaction between Comt and Bdnf variants influences obsessive-compulsive-related dysfunctional beliefs. J Anxiety Disord (2013) 27(3):321–7.10.1016/j.janxdis.2013.02.01223602946HallDDhillaACharalambousAGogosJAKarayiorgouM. Sequence variants of the brain-derived neurotrophic factor (BDNF) gene are strongly associated with obsessive-compulsive disorder. Am J Hum Genet (2003) 73:370–6.10.1086/37700312836135HemmingsSMKinnearCJVan der MerweLLochnerCCorfieldVAMoolman-SmookJCInvestigating the role of the brain-derived neurotrophic factor (BDNF) val66met variant in obsessive-compulsive disorder (OCD). World J Biol Psychiatry (2008) 9:126–34.10.1080/152297070124500317853300KaterbergHLochnerCCathDCde JongePBochdanovitsZMoolman-SmookJCThe role of brain-derived neurotrophic factor (BDNF) val66met variant in the phenotypic expression of obsessive-compulsive disorder (OCD). Am J Med Genet B Neuropsychiatr Genet (2009) 150B:1050–62.10.1002/ajmg.b.30930MárquezLCamarenaBHernándezSLóyzagaCVargasLNicoliniH. Association study between BDNF gene variants and Mexican patients with obsessive-compulsive disorder. Eur Neuropsychopharmacol (2013) 23(11):1600–5.10.1016/j.euroneuro.2013.08.00123999029HemmingsSMLochnerCVan der MerweLCathDCSeedatSSteinDJ. BDNF Val66Met modifies the risk of childhood trauma on obsessive-compulsive disorder. J Psychiatr Res (2013) 47(12):1857–63.10.1016/j.jpsychires.2013.08.01224050777ForrayAFocseneanuMPittmanBMcDougleCJEppersonCN. Onset and exacerbation of obsessive-compulsive disorder in pregnancy and the postpartum period. J Clin Psychiatry (2010) 71(8):1061–8.10.4088/JCP.09m05381blu20492843AlonsoPGratacòsMSegalàsCEscaramísGRealEBayésMVariants in estrogen receptor alpha gene are associated with phenotypical expression of obsessive-compulsive disorder. Psychoneuroendocrinology (2011) 36(4):473–83.10.1016/j.psyneuen.2010.07.022WegererMKerschbaumHBlechertJWilhelmFH. Low levels of estradiol are associated with elevated conditioned responding during fear extinction and with intrusive memories in daily life. Neurobiol Learn Mem (2014) 116:145–54.10.1016/j.nlm.2014.10.00125463649MattheisenMSamuelsJFWangYGreenbergBDFyerAJMcCrackenJTGenome-wide association study in obsessive-compulsive disorder: results from the OCGAS. Mol Psychiatry (2015) 20:337–44.10.1038/mp.2014.4324821223JaenischRBirdA. Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals. Nature Genet (2003) 33:245–54.10.1038/ng108912610534MillerCASweattJD. Covalent modification of DNA regulates memory formation. Neuron (2007) 53(6):857–69. Erratum in: Neuron (2008) 59(6):1051.10.1016/j.neuron.2007.02.022DomschkeKTidowNSchrempfMSchwarteKKlaukeBReifAEpigenetic signature of panic disorder: a role of glutamate decarboxylase 1 (GAD1) DNA hypomethylation?Prog Neuropsychopharm Biol Psychiatry (2013) 46:189–96.10.1016/j.pnpbp.2013.07.01423906988RobertsSLesterKJHudsonJLRapeeRMCreswellCCooperPJSerotonin transporter methylation and response to cognitive behaviour therapy in children with anxiety disorders. Transl Psychiatry (2014) 4(9):e444.10.1038/tp.2014.83KaufmanJBirmaherBBrentDRaoUFlynnCMoreciPSchedule for affective disorders and schizophrenia for school-age children-present and lifetime version (K-SADS-PL): initial reliability and validity data. J Am Acad Child Adolesc Psychiatry (1997) 36(7):980–8.10.1097/00004583-199707000-000219204677ScahillLRiddleMAMcSwiggin-HardinMOrtSIKingRAGoodmanWKChildren’s Yale-Brown Obsessive Compulsive Scale: reliability and validity. J Am Acad Child Adolesc Psychiatry (1997) 36(6):844–52.10.1097/00004583-199706000-000239183141HollegaardMVGrauholmJBørglumANyegaardMNørgaard-PedersenBØrntoftTGenome-wide scans using archived neonatal dried blood spot samples. BMC Genomics (2009) 10:297.10.1186/1471-2164-10-29719575812WinkelBGHollegaardMVOlesenMSSvendsenJHHaunsøSHougaardDMWhole-genome amplified DNA from stored dried blood spots is reliable in high resolution melting curve and sequencing analysis. BMC Med Genet (2011) 12:22.10.1186/1471-2350-12-2221306642HollegaardMVGroveJGrauholmJKreiner-MøllerEBønnelykkeKNørgaardMRobustness of genome-wide scanning using archived dried blood spot samples as a DNA source. BMC Genet (2011) 12:58.10.1186/1471-2156-12-5821726430MorrisTJButcherLMFeberATeschendorffAEChakravarthyARWojdaczTKChAMP: 450k chip analysis methylation pipeline. Bioinformatics (2014) 30(3):428–30.10.1093/bioinformatics/btt68424336642NordlundJBäcklinCLWahlbergPBuscheSBerglundECElorantaMLGenome-wide signatures of differential DNA methylation in pediatric acute lymphoblastic leukemia. Genome Biol (2013) 14(9):r105.10.1186/gb-2013-14-9-r10524063430WaltonEHassJLiuJRoffmanJLBernardoniFRoessnerVCorrespondence of DNA methylation between blood and brain tissue and its application to schizophrenia research. Schizophr Bull (2015) 42(2):406–14.10.1093/schbul/sbv074SulimanSHemmingsSMSeedatS. Brain-derived neurotrophic factor (BDNF) protein levels in anxiety disorders: systematic review and metaregression analysis. Front Integr Neurosci (2013) 7:55.10.3389/fnint.2013.00055AnderoRResslerKJ. Fear extinction and BDNF: translating animal models of PTSD to the clinic. Genes Brain Behav (2012) 11(5):503–12.10.1111/j.1601-183X.2012.00801.x22530815AndreskaTAufmkolkSSauerMBlumR. High abundance of BDNF within glutamatergic presynapses of cultured hippocampal neurons. Front Cell Neurosci (2014) 8:107.10.3389/fncel.2014.0010724782711ArnoldPDSicardTBurroughsERichterMAKennedyJL. Glutamate transporter gene SLC1A1 associated with obsessive–compulsive disorder. Arch Gen Psychiatry (2006) 63:769–76.10.1001/archpsyc.63.7.769StewartSEFagernessJAPlatkoJSmollerJWScharfJMIllmannCAssociation of the SLC1A1 glutamate transporter gene and obsessive–compulsive disorder. Am J Med Genet B Neuropsychiatr Genet (2007) 144B:1027–33.10.1002/ajmg.b.30533AlonsoPGratacosMMenchonJMSaiz-RuizJSegalàsCBaca-GarcíaEExtensive genotyping of the BDNF and NTRK2 genes define protective haplotypes against obsessive–compulsive disorder. Biol Psychiatry (2008) 63:619–28.10.1016/j.biopsych.2007.06.020MossnerRWalitzaSLeschKPGellerFBarthNRemschmidtHBrain-derived neurotrophic factor V66M polymorphism in childhood-onset obsessive–compulsive disorder. Int J Neuropsychopharmacol (2005) 8:133–6.10.1017/S146114570400495XBlochMHLanderos-WeisenbergerARosarioMCPittengerCLeckmanJF. Meta-analysis of the symptom structure of obsessive–compulsive disorder. Am J Psychiatry (2008) 165:1532–42.10.1176/appi.ajp.2008.08020320WalitzaSMarinovaZGrünblattELazicSERemschmidtHVloetTDTrio study and meta-analysis support the association of genetic variation at the serotonin transporter with early-onset obsessive-compulsive disorder. Neurosci Lett (2014) 580:100–3.10.1016/j.neulet.2014.07.03825093702WalitzaSScheragARennerTJHinneyARemschmidtHHerpertz-DahlmannBTransmission disequilibrium studies in early onset of obsessive–compulsive disorder for polymorphisms in genes of the dopaminergic system. J Neural Transm (2008) 115:1071–8.10.1007/s00702-008-0051-6DelgrangeEVasiljevicAWierinckxAFrancoisPJouanneauERaverotGExpression of estrogen receptor alpha is associated with prolactin pituitary tumor prognosis and supports the sex-related difference in tumor growth. Eur J Endocrinol (2015) 172(6):791–801.10.1530/EJE-14-0990LujanRShigemotoRLopez-BenditoG. Glutamate and GABA receptor signalling in the developing brain. Neuroscience (2005) 130(3):567–80.10.1016/j.neuroscience.2004.09.04215590141DempsterELPidsleyRSchalkwykLCOwensSGeorgiadesAKaneFDisease-associated epigenetic changes in monocygotic twins discordant for schizophrenia and bipolar disorder. Hum Mol Genet (2011) 20(24):4786–96.10.1093/hmg/dd416UddinMSipahiLLiJKoenenKC. Sex differences in DNA methylation may contribute to risk of PTSD and depression: a review of existing evidence. Depress Anxiety (2013) 30(12):1151–60.10.1002/da.2216723959810